Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias

Trial Profile

A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias

Phase of Trial: Phase I/II

Latest Information Update: 17 Jun 2018

At a glance

  • Drugs Bosutinib (Primary)
  • Indications Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Pharmacokinetics; Registrational; Therapeutic Use
  • Sponsors Pfizer; Wyeth Pharmaceuticals
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 17 Jun 2018 Results assessing cross-intolerance (adverse events leading to discontinuation of both prior TKI and bosutinib) presented at the 23rd Congress of the European Haematology Association
    • 05 Jun 2018 Results of retrospective analysis assessing effects of bosutinib on renal function by using data from two studies including this study published in the Clinical Lymphoma, Myeloma & Leukemia.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top